肠道激素与肥胖和糖尿病

来自：中国糖尿病杂志编辑：杨文英|点击数：|2016-03-03

【提要】肥胖和T2DM的病理生理学机制相当复杂。近年发现,肥胖及T2DM患者的肠道激素水平发生改变，肠道激素，如胰升血糖素样肽-1（GLP-1）、糖依赖性胰岛素释放肽（GIP）、酪酪肽（PYY）、胆囊收缩素（CCK）、胃促生长素与肥胖及糖尿病的发生发展密切相关，可导致一系列代谢障碍，可能是引起肥胖及T2DM发生发展的病因之一。以肠道激素为基础或与之相关的治疗方案成为近年来糖尿病研究领域的热点方向之一。目前，部分基于肠道激素的治疗手段已应用于糖尿病的临床治疗。本文就肠道激素的认识历程、肠道激素影响糖尿病和肥胖发生的机制，以及临床应用等方面作一综述。

【关键词】肠道激素；糖尿病，2型；肥胖

Gut hormones in obesity and diabetes

【Summary】 Pathophysiological mechanisms of obesity and type 2 diabetes is complex .In recent years, data has showed that guthormone in obesity and T2DM patients has changed, and guthormones such as GLP-1, GIP, PYY, CCK and ghrelin are strongly related to the development of obesity and diabetes, resulting in a series of metabolic disorders, this may be one of causes of the development of obesity and T2DM.In recent years ,the guthormone-based treatments or therapies associated with guthormone have became one of the hot topics in the diabetes research. Currently, some guthormone-based treatment shave been used in clinical treatment of diabetes. This paper is a literature review on the history of gut hormones, and how it affect the development of diabetes and obesity, as well as aspects of clinical practice.

【Key words】 Gut hormones；Diabetes mellitus，type 2；Obesity

上一篇：糖耐量减低的药物干预下一篇：美国临床内分泌医师协会2015年版糖尿病综合管理临床实践指南的解读

《中国糖尿病杂志》官方网站

编辑部在线

联系我们

肠道激素与肥胖和糖尿病

相关阅读

热门推荐